ELEDON PHARMACEUTICALS INC (ELDN) Stock Price, Quote, News and Overview
NASDAQ:ELDN - Nasdaq - US28617K1016 - Common Stock - Currency: USD
ELDN Quote, Performance and Key Statistics
NASDAQ:ELDN (5/23/2025, 9:29:55 PM)
3.05
+0.03 (+0.99%)
The current stock price of ELDN is 3.05 USD. In the past month the price decreased by -5.86%. In the past year, price increased by 8.16%.
ELDN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 323.71B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About ELDN
Company Profile
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Company Info
ELEDON PHARMACEUTICALS INC
19800 Macarthur Blvd., Suite 250
Irvine CALIFORNIA 92612 US
CEO: David-Alexandre C. Gros
Employees: 20
Phone: 19492388090
ELEDON PHARMACEUTICALS INC / ELDN FAQ
What is the stock price of ELEDON PHARMACEUTICALS INC today?
The current stock price of ELDN is 3.05 USD. The price increased by 0.99% in the last trading session.
What is the ticker symbol for ELEDON PHARMACEUTICALS INC stock?
The exchange symbol of ELEDON PHARMACEUTICALS INC is ELDN and it is listed on the Nasdaq exchange.
On which exchange is ELDN stock listed?
ELDN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ELEDON PHARMACEUTICALS INC stock?
12 analysts have analysed ELDN and the average price target is 10.61 USD. This implies a price increase of 247.8% is expected in the next year compared to the current price of 3.05. Check the ELEDON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ELEDON PHARMACEUTICALS INC worth?
ELEDON PHARMACEUTICALS INC (ELDN) has a market capitalization of 182.63M USD. This makes ELDN a Micro Cap stock.
How many employees does ELEDON PHARMACEUTICALS INC have?
ELEDON PHARMACEUTICALS INC (ELDN) currently has 20 employees.
What are the support and resistance levels for ELEDON PHARMACEUTICALS INC (ELDN) stock?
ELEDON PHARMACEUTICALS INC (ELDN) has a support level at 2.86 and a resistance level at 3.29. Check the full technical report for a detailed analysis of ELDN support and resistance levels.
Should I buy ELEDON PHARMACEUTICALS INC (ELDN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ELDN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ELDN, evaluating the profitability, health, valuation and growth aspects
- ELEDON PHARMACEUTICALS INC (ELDN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ELEDON PHARMACEUTICALS INC (ELDN) Sales and EPS estimates to see what analysts future expectations are.
- ELEDON PHARMACEUTICALS INC (ELDN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ELEDON PHARMACEUTICALS INC (ELDN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ELEDON PHARMACEUTICALS INC (ELDN) Stock Chart to make your own analysis
- ELEDON PHARMACEUTICALS INC (ELDN) Latest news and press-releases to stay up to date.
Does ELEDON PHARMACEUTICALS INC (ELDN) stock pay dividends?
ELDN does not pay a dividend.
When does ELEDON PHARMACEUTICALS INC (ELDN) report earnings?
ELEDON PHARMACEUTICALS INC (ELDN) will report earnings on 2025-08-18.
What is the Price/Earnings (PE) ratio of ELEDON PHARMACEUTICALS INC (ELDN)?
ELEDON PHARMACEUTICALS INC (ELDN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.79).
What is the Short Interest ratio of ELEDON PHARMACEUTICALS INC (ELDN) stock?
The outstanding short interest for ELEDON PHARMACEUTICALS INC (ELDN) is 3.09% of its float. Check the ownership tab for more information on the ELDN short interest.
ELDN Technical Analysis
ELDN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ELDN. No worries on liquidiy or solvency for ELDN as it has an excellent financial health rating, but there are worries on the profitability.
ELDN Financial Highlights
Over the last trailing twelve months ELDN reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 42.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.72% | ||
| ROE | -50.63% | ||
| Debt/Equity | 0 |
ELDN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to ELDN. The Buy consensus is the average rating of analysts ratings from 12 analysts.